Aurora Kinase B Global Market Report 2025

What Are the Market Size and Growth Forecast for the Aurora Kinase B Market?
In recent times, the market size for aurora kinase b has witnessed a fast-paced growth. The market that was worth $1.14 billion in 2024 is forecasted to rise to $1.27 billion in 2025, boasting a compound annual growth rate of 12.1%. Factors contributing to this growth during the historic period include the escalating demand for cancer-specific therapies, an uptick in worldwide cancer prevalence, increased investment in precision medicine, growth in clinical trials, and increased government funding for cancer research.

The market size for aurora kinase b is predicted to witness a swift expansion in the coming years, reaching approximately $1.99 billion by 2029 with a compound annual growth rate (CAGR) of 11.8%. The anticipated growth during the forecast period is mainly due to increased investments in inventive cancer treatments, the growing incidence of drug-resistant cancers, expanding research and development initiatives, an escalating demand for combination therapies, and the increasing prevalence of solid tumors. Key trends expected during the forecast period encompass technological innovation, precision medicine, new treatment methods, data analytics, and pioneering therapies.

What Is Contributing to the Growth of the Aurora Kinase B Market?
The surge in cancer cases is predicted to fuel the expansion of the aurora kinase B market. Categorized by uncontrolled growth and the dispersion of abnormal cells that can encroach on surrounding tissues and spread to various parts of the body, cancer is an aggregation of various diseases. The escalating instances of cancer are attributed to an aging populace, changes in lifestyle, exposure to harmful environmental factors, and advancements in detection and diagnosis methodologies. Aurora kinase B is crucial to mitosis. Its over-expression is associated with chromosomal instability and cancer advancement, thus making it a usual target in cancer treatments. To illustrate, the World Health Organization, an intergovernmental body based in Switzerland, reported an estimated 20 million new cancer cases and 9.7 million deaths in 2022 alone. By 2050, it's projected that new cancer cases will skyrocket to more than 35 million, indicating a 77% rise from 2022. As such, the escalating occurrence of cancer is a key driver for the growth of the aurora kinase B market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20496&type=smp

Which Key Market Leaders Are Driving Aurora Kinase B Industry Growth?
Major companies operating in the aurora kinase B market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Astellas Pharma Inc., Promega Corporation, Rigel Pharmaceuticals Inc., Tocris Bioscience, BPS Bioscience Inc., Advenchen Laboratories LLC, Shenzhen Chipscreen Biosciences Co. Ltd., Cyclacel Pharmaceuticals Inc., Sareum Holdings plc

Which Key Market Leaders Are Driving Industry Growth?
Leading firms in the aurora kinase B market are pioneering new products, like aurora kinase inhibitors, dedicated to disrupting essential cell division processes. These inhibitors are medications engineered to obstruct Aurora kinases activities crucial to cell division, which in-turn sabotage cancer cell growth and can possibly lessen tumour expansion. For example, in June 2023, Ellipses Pharma, a biotechnology firm from the UK, received approval from the U.S. Food and Drug Administration (FDA) for EP0042, a dual FLT-3 and Aurora kinase inhibitor. EP0042 is under process to become a remedy for acute myeloid leukemia (AML) by inhibiting both FLT3 and Aurora kinase. This method is exclusively designed for AML patients who have developed a resistance to FLT3 inhibitors. Studies have shown that dual obstruction of FLT3 and Aurora kinase can defeat acquired resistance to selective FLT3 obstruction both in vitro and in vivo.

What Are the Main Segments in the Aurora Kinase B Market?
The aurora kinase b market covered in this report is segmented -

1) By Type: AZD-2811, CS-2164, Danusertib, Ilorasertib, NMI-900, Other Types
2) By Application: Anaplastic Large Cell Lymphoma, Kidney Cancer, Lung Cancer, Prostate Cancer, Other Applications
3) By End-User: Hospitals, Research Institutes, Diagnostic Laboratories, Other End-Users

Subsegments:
1) By AZD-2811: Phase I Clinical Trials AZD-2811, Preclinical Development of AZD-2811, AZD-2811 in Combination Therapy, Targeted Cancer Treatment with AZD-2811
2) By CS-2164: Phase II Clinical Trials CS-2164, Preclinical Development of CS-2164, CS-2164 in Targeted Cancer Therapy, CS-2164 Combination Therapy in Clinical Studies
3) By Danusertib: Phase III Clinical Trials Danusertib, Danusertib for Hematological Malignancies, Danusertib for Solid Tumors, Combination Therapy with Danusertib
4) By Ilorasertib: Preclinical Development of Ilorasertib, Ilorasertib in Solid Tumor Treatment, Phase I and II Clinical Trials of Ilorasertib, Ilorasertib in Combination with Chemotherapies
5) By NMI-900: NMI-900 in Early-Stage Clinical Trials, NMI-900 for Targeted Cancer Therapy, Preclinical Studies of NMI-900, NMI-900 Combination Therapy Trials
6) By Other Types: Other Aurora Kinase B Inhibitors in Development, Novel Targeted Aurora Kinase B Drugs, Combination Therapies Involving Aurora Kinase B Inhibitors, Investigational Aurora Kinase B Inhibitors in Oncology

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/aurora-kinase-b-global-market-report

Which Geographic Area Leads the Aurora Kinase B Market?
North America was the largest region in the aurora kinase B market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Aurora Kinase B Global Market Report?

- Market Size Analysis: Analyze the aurora kinase b Market Size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the aurora kinase b market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall aurora kinase b market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the aurora kinase b market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20496

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.